WuXi AppTec Co., Ltd. (2359.HK)
Chart Events
Performance Outlook
| Previous Close | 171.100 |
| Open | 171.100 |
| Bid | 165.800 x 0 |
| Ask | 165.900 x 0 |
| Day's Range | 164.200 - 173.900 |
| 52 Week Range | 70.214 - 216.000 |
| Volume | 1,952,814 |
| Avg. Volume | 2,415,562 |
| Market Cap | 427.227B |
| Beta (5Y Monthly) | 0.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.43 (0.24%) |
| Ex-Dividend Date | May 28, 2021 |
| 1y Target Est | N/A |
- PR Newswire
WuXi AppTec Reports Record First-Quarter 2021 Results
WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for the First-Quarter of 2021 ("Reporting Period").
- PR Newswire
WuXi AppTec Reports Strong 2020 Annual Results
WuXi AppTec (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its audited annual results for the year ended December 31, 2020 ("Reporting Period").
- PR Newswire
WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers
WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.
